Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05534789 · ClinicalTrials.gov registry record
Treatment Patterns and Clinical Outcomes Among Patients With Advanced Renal Cell Carcinoma (aRCC) Receiving Systemic First-line (1st Line) Anti-cancer Treatment Under Daily Routine in Germany: Retrospective Medical Chart Review (RENALISTIC Study).
A clinical trial, sponsored by Pfizer.
- Terminated
- Registry status
- 106
- Enrollment target
NCT05534789 is a clinical trial that was terminated before completion, run by Pfizer. The registered enrollment target is 106 participants.
The verdict
NCT05534789 was terminated before completion, sponsored by Pfizer.
- TERMINATED
- Registry status
- 106 participants
- Enrollment target
Study Summary
The purpose of this study is to learn about the treatments used in for advanced renal cell carcinoma as well as effectiveness of these treatments in the real world. Study participants must be: At least 18 years of age or older. Confirmed renal cell carcinoma Received first line treatment
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 106 participants |
| Start Date | 2022-10-15 |
| Est. Completion | 2023-12-13 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05534789
The ClinicalTrials.gov registry entry for NCT05534789 describes a study currently listed as terminated, categorized as an unspecified phase. The registered enrollment target is 106 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 0 interventions.
NCT05534789 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05534789 about?
NCT05534789 is a clinical study titled "Treatment Patterns and Clinical Outcomes Among Patients With Advanced Renal Cell Carcinoma (aRCC) Receiving Systemic First-line (1st Line) Anti-cancer Treatment Under Daily Routine in Germany: Retrospective Medical Chart Review (RENALISTIC Study).". The purpose of this study is to learn about the treatments used in for advanced renal cell carcinoma as well as effectiveness of these treatments in the real world. Study participants must be: At least 18 years of age or older. Confirmed renal cell carcinoma Received first line treatment
What is the current status of trial NCT05534789?
This trial is currently terminated. The enrollment target is 106 participants. The study started on 2022-10-15. Estimated completion is 2023-12-13.
Who is sponsoring clinical trial NCT05534789?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.